XGN Exagen

Exagen Announces Addition to Russell 3000® and 2000® Indexes

Exagen Announces Addition to Russell 3000® and 2000® Indexes

SAN DIEGO, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that it will be added to the Russell 3000® and 2000® Indexes, effective after the US market opens on December 23, 2019. Membership in the U.S. all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the small-cap Russell 2000® Index based on Exagen’s market capitalization. Exagen will also be added to the appropriate growth and value style indexes.

“We are pleased to have earned inclusion in the widely recognized Russell indexes,” said Ron Rocca, CEO of Exagen. “This is an important milestone in Exagen’s growth, and reflects the value the market places upon our ability to significantly improve outcomes for patients suffering from autoimmune diseases.”

Russell US Indexes are widely used by investment managers and institutional investors as the basis for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell US Indexes. Russell US Indexes are part of FTSE Russell’s suite of index offerings.

For more information on the Russell US Indexes, go to the .

About Exagen Inc.

Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE® brand, several of which are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen’s goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis.

CONTACTS:

Investors

Westwicke Partners

Mike Cavanaugh



646.677.1838



Media

Exagen Inc.

Kamal Adawi



760.477.5514

EN
16/12/2019

Underlying

XGNExagen

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Exagen

 PRESS RELEASE
Free
XGN EXAGEN

Exagen Inc. to Participate in Fourth Quarter Investor Conferences

Exagen Inc. to Participate in Fourth Quarter Investor Conferences CARLSBAD, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following upcoming investor conferences: 16th Annual Craig-Hallum Alpha Select Conference Date: November 18, 2025 Location: Sheraton New York Times Square Hotel Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum Date: November 20, 2025 Location: Westin NY Grand Central - 212 E 42nd Street New York, NY 10017 About Exagen...

November 11, 2025 1 EN
 PRESS RELEASE
Free
XGN EXAGEN

Exagen Inc. Reports Strong Q3 2025 Results

Exagen Inc. Reports Strong Q3 2025 Results CARLSBAD, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2025, and recent corporate updates.   Three Months Ended September 30, Nine Months Ended September 30,  2025 2024 2025 2024(Unaudited, in thousands, except ASP data)  Revenue $17,244  $12,507  $49,944  $41,986 Gross margin  58.4%  55.8%  59.3%  58.7%Operating expenses $13,175  $11,644  $38,688  $34,888 Operating loss $(3,100) $(4,663) $(9,095) $(10,2...

November 4, 2025 1 EN
 PRESS RELEASE
Free
XGN EXAGEN

Exagen Announces Acceptance of Six Abstracts at 2025 American College ...

Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of six abstracts at the 2025 American College of Rheumatology’s (ACR) annual meeting, ACR Convergence 2025, being held October 24-29, 2025, at the McCormick Place Convention Center in Chicago, Illinois. Exagen’s featured plenary presentation, in collaboration with Johns Hopkins University, will highlight a urinary biomarker panel that holds t...

October 23, 2025 1 EN
 PRESS RELEASE
Free
XGN EXAGEN

Exagen Inc. to Announce Third Quarter 2025 Financial Results on Novemb...

Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025 CARLSBAD, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended September 30, 2025, before the market opens on Tuesday, November 4, 2025. John Aballi, Exagen’s President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company’s results at 8:30 a.m. ET (5:30 a.m. PT). Conference Call & Webcast: U.S. dial-in: 201-389-0918Intern...

October 21, 2025 1 EN
 PRESS RELEASE
Free
XGN EXAGEN

Exagen Inc. to Participate in Third Quarter Investor Conferences

Exagen Inc. to Participate in Third Quarter Investor Conferences CARLSBAD, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, today announced that management will participate in the following upcoming investor conferences: Canaccord Genuity 45th Annual Growth Conference Participation: Fireside Chat and 1X1 Meetings Date: Tuesday, August 12, 2025 Location: InterContinental Hotel in Boston, MA Cantor Global Healthcare Conference 2025 Participation: Fireside Chat and 1X1 Meetings Date: W...

August 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch